Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
190 hedge funds and large institutions have $278M invested in Esperion Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 55 increasing their positions, 44 reducing their positions, and 25 closing their positions.
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
26% more call options, than puts
Call options by funds: $5.22M | Put options by funds: $4.13M
25% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 44
15% more capital inflows, than outflows
Capital inflows: $40.6M | Capital outflows: $35.3M
4% more funds holding
Funds holding: 183 → 190 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.91% less ownership
Funds ownership: 66.02% → 64.11% (-1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$8.55M |
| 2 |
ICM
Indaba Capital Management
San Francisco,
California
|
+$7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.78M |
| 4 |
Goldman Sachs
New York
|
+$3.37M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$5.1M |
| 3 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$4.21M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.25M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.1M |
ESPR Hedge Fund Activity: Q4 2024 in Review
190 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q4 2024, worth a combined $278M — up 30% from $214M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new ESPR positions and 25 closed out — a net gain of 9 holders — while 55 added to existing stakes and 44 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $8.55M. The largest seller was Millennium Management, cutting an estimated $6M.
- 190 institutional investors held Esperion Therapeutics (ESPR) as of Q4 2024, up from 183 in Q3 2024.
- Funds reported $278M of Esperion Therapeutics stock for Q4 2024, up 30% quarter-over-quarter.
- 34 funds opened new Esperion Therapeutics positions in Q4 2024 and 25 closed out, a net change of +9 holders.
- The largest Esperion Therapeutics buyer in Q4 2024 was Morgan Stanley, an estimated $8.55M added.
- The largest Esperion Therapeutics seller in Q4 2024 was Millennium Management, an estimated $6M sold.
Based on aggregated 13F filings for Q4 2024.